Brief: Salarius Pauses New Patient Enrollment In Phase 1/2 Trial For Sarcomas Treatment
18/10/2022 13:42
Oct 18 (Reuters) - Salarius Pharmaceuticals Inc
SLRX.O :
* SALARIUS PHARMACEUTICALS ANNOUNCES PAUSE IN NEW PATIENT
ENROLLMENT IN ITS PHASE 1/2 TRIAL OF SECLIDEMSTAT IN EWING
SARCOMA AND FET-REARRANGED SARCOMAS
* SALARIUS PHARMA- PAUSE IS DUE TO METASTATIC FET-REARRANGED
SARCOMA PATIENT DEATH THAT WAS CLASSIFIED AS SUSPECTED
UNEXPECTED SERIOUS ADVERSE REACTION
Source text for Eikon: ID:nGNX50zYXl
Further company coverage: SLRX.O
((Reuters.Briefs@thomsonreuters.com;))